In vitro affinity optimization of an anti-BDNF monoclonal antibody translates to improved potency in targeting chronic pain states in vivo

• Egile Nagusiak: Edwina Stack (Egilea), Sheridan McMurray (Egilea), Gordon McMurray (Egilea), Jason Wade (Egilea), Melissa Clark (Egilea), Gareth Young (Egilea), Kim Marquette (Egilea), Sadhana Jain (Egilea), Kerry Kelleher (Egilea), Ting Chen (Egilea), Qingcong Lin (Egilea), Laird Bloom (Egilea), Laura Lin (Egilea), William Finlay (Egilea), Rie Suzuki (Egilea), Orla Cunningham (Egilea)
• Formatua: Liburua
• Argitaratua: Taylor & Francis Group, 2020-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

The role of brain-derived neurotrophic factor (BDNF) signaling in chronic pain has been well documented. Given the important central role of BDNF in long term plasticity and memory, we sought to engineer a high affinity, peripherally-restricted monoclonal antibody against BDNF to modulate pain. BDNF...